Table 4: Comparison between the non-high-dose and high-dose PPI after case-controlled matching.

CharacteristicNon-high-dose group ( )High-dose group ( ) value

Age (years) 0.121
Female gender, (%)11 (25)12 (27.3)0.808
Creatinine (mg/dL) 0.615
Hb (g/L) 0.897
Platelet (×109/L) 0.297
Use of NSAIDs, (%)3 (6.8)2 (4.5)0.696
Use of aspirin, (%)4 (9.1)5 (11.4)0.725
Use of clopidogrel, (%)3 (6.8)4 (9.1)0.694
Use of warfarin, (%)1 (2.3)2 (4.5)0.557
Coexisting illness, (%)
 CKD III, IV/V19/613/70.410
 COPD100.315
 CAD6100.269
 DM12140.640
 CVA1270.195
 Liver cirrhosis1080.597
Shock oat presentation24280.386
Rockall score 0.387
Time to endoscope (hours) 0.299
PRBC BT (mL) 1496.5 0.537
Forrest classification Ia/Ib/IIa/IIb/IIc/III2/28/1/131/28/4/110.513
Time to oral PPI (days) 0.016*
Rebleeding, (%)8 (18.2)7 (15.9)0.777
Surgery, (%)001.000
Hospital stay (days) 0.505
Mortality, (%)5 (11.4)3 (6.8)0.359
Bleeding related/other causes3/23/0

Hb: hemoglobin, NSAID: nonsteroidal anti-inflammatory drug, CKD: chronic kidney disease, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton-pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. * .